Olshan Grundman Frome Rosenzweig & Wolosky
Park Avenue Tower
65 East 55th Street
New York, NY 10022
Tel: 212.451.2300

New Jersey Office
744 Broad Street
Newark, NJ 07102
Tel: 973.331.7200
Olshan Grundman Frome Rosenzweig & Wolosky LLP is a premier New York law firm for businesses, investors and entrepreneurs. We have been consistently recognized for our expertise in corporate and securities law, shareholder activism, real estate, intellectual property, tax, litigation, and bankruptcy and creditors' rights. In addition we have significant practices in employee benefits and employment practices.

Olshan's top disciplines include:
  • Mergers and acquisitions
  • Proxy contests
  • Securities and commercial litigation
  • Commercial real estate leasing
  • Trademark enforcement
  • Venture capital
  • Financings
  • Joint ventures
  • Real estate development
  • Workouts
Our cost-effective, personal service is tailored to the specific concerns of each client, from large corporations to small businesses and individuals. Contact Olshan and see how our dedicated service and creative solutions can benefit you.


Olshan Grundman Frome Rosenzweig & Wolosky LLP Privacy Policy.
This website constitutes Attorney Advertising under New York court rules.
Prior results do not guarantee a similar outcome.
August 12, 2010
WSJ Covers Wolosky's Successful LaGrange Campaign at Forward
The Wall Street Journal recently reported on the successful negotiation of a settlement by... Read >
August 5, 2010
Udell Quoted in Journal
The New York Law Journal quoted Jeffrey A. Udell, chair of the New York City Bar Associati... Read >
August 3, 2010
Berets and Ross Handle Omnispective Lease with Grom
The New York Times ran a story on high-end ice cream shops and mentioned two Grom gelate... Read >
August 3, 2010
Gursky Handles Michael Kors Lease in Manhattan
The New York Post reported on the lease by fashion retailer Michael Kors for 2,500 squar... Read >
July 19, 2010
Wolosky Leads Bid for Cypress Bioscience
Olshan's client Ramius LLC offered to buy drugmaker Cypress Bioscience Inc. for approximat... Read >